Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/27/3/373/6675777/mdv562.pdf
Reference51 articles.
1. Food and Drug Administration requirements for approval of new anticancer drugs;Johnson;Cancer Treat Rep,1985
2. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?;Saad;J Clin Oncol,2012
3. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials;Saad;J Clin Oncol,2010
4. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer;Hayashi;Ann Oncol,2012
5. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer;Petrelli;Ann Oncol,2013
Cited by 60 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The evolving value assessment of cancer therapies: Results from a modified Delphi study;Health Policy OPEN;2024-12
2. Competing Risks and Multistate Modelsin Oncology Clinical Trials;Japanese Journal of Biometrics;2024-07-30
3. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC;Journal of Thoracic Oncology;2024-07
4. Beyond the median: Estimating survival times for patients starting endocrine therapy for estrogen receptor‐positive, metastatic breast cancer from recent randomized trials;Asia-Pacific Journal of Clinical Oncology;2024-06-16
5. The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials;Annals of Internal Medicine;2024-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3